A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis-related hepatocellular carcinoma

Journal of Viral Hepatitis

Volumn 20, Issue 10, 2013, Pages 729-743

  Huang, T S ^a,e   Shyu, Y C ^b,c   Chen, H Y ^a   Yuan, S S ^d   Shih, J N ^a   Chen, P J ^e,f  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

adjuvant therapy; hepatocellular carcinoma; interferon; liver cancer; meta analysis; viral hepatitis

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; INTERFERON; INTERFERON ALPHA 1B; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG;

CANCER ADJUVANT THERAPY; CANCER SURVIVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS;

ADJUVANT THERAPY; HEPATOCELLULAR CARCINOMA; INTERFERON; LIVER CANCER; META-ANALYSIS; VIRAL HEPATITIS;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B; HEPATITIS C; HUMANS; IMMUNOLOGIC FACTORS; INTERFERONS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84884134482     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12096     Document Type: Review

References (53)

1. Bosch FX, Ribes J, Diaz M, Cleries R,. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127 (5 Suppl. 1): S5-S16.
2. Altekruse SF, McGlynn KA, Reichman ME,. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27 (9): 1485-1491.
3. Song TJ, Ip EW, Fong Y,. Hepatocellular carcinoma: current surgical management. Gastroenterology 2004; 127 (5 Suppl. 1): S248-S260.
4. Pawlik TM, Esnaola NF, Vauthey JN,. Surgical treatment of hepatocellular carcinoma: similar long-term results despite geographic variations. Liver Transpl 2004; 10 (2 Suppl. 1): S74-S80.
5. Mazzaferro V, Regalia E, Doci R, et al,. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11): 693-699.
6. Shimada M, Takenaka K, Gion T, et al,. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996; 111 (3): 720-726.
7. Kishi Y, Hasegawa K, Sugawara Y, Kokudo N,. Hepatocellular carcinoma: current management and future development-improved outcomes with surgical resection. Int J Hepatol 2011; 2011: 728103.
8. Chiu JH, Wu LH, Kao HL, et al,. Can determination of the proliferative capacity of the nontumor portion predict the risk of tumor recurrence in the liver remnant after resection of human hepatocellular carcinoma? Hepatology 1993; 18 (1): 96-102.
9. Hoshida Y, Villanueva A, Kobayashi M, et al,. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359 (19): 1995-2004.
10. Kudo M,. Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology 2011; 81 (Suppl. 1): 50-55.
11. Yano H, Ogasawara S, Momosaki S, et al,. Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int 2006; 26 (8): 964-975.
12. Ikeda K, Arase Y, Saitoh S, et al,. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32 (2): 228-232.
13. Kubo S, Nishiguchi S, Hirohashi K, et al,. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 134 (10): 963-967.
14. Lin SM, Lin CJ, Hsu CW, et al,. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004; 100 (2): 376-382.
15. Mazzaferro V, Romito R, Schiavo M, et al,. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44 (6): 1543-1554.
16. Chen LT, Chen MF, Li LA, et al,. Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 2012; 255 (1): 8-17.
17. Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ge YS,. Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials. Int J Cancer 2011; 129 (5): 1254-1264.
18. Singal AK, Freeman DH Jr, Anand BS,. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 32 (7): 851-858.
19. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL,. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol 2010; 52 (6): 889-894.
20. Miyake Y, Takaki A, Iwasaki Y, Yamamoto K,. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 2010; 17 (4): 287-292.
21. Miao RY, Zhao HT, Yang HY, et al,. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol 2010; 16 (23): 2931-2942.
22. Forner A, Llovet JM, Bruix J,. Hepatocellular carcinoma. Lancet 2012; 379 (9822): 1245-1255.
23. Huang TS, Shyu YC, Shih JN, Chen PJ, Yuan SS,. A systematic review and meta-analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis related hepatocellular carcinoma. PROSPERO 2012:CRD42012002419. Available at: http://www.crd.york.ac.uk/PROSPERO/display- record.asp?ID=CRD42012002419 (accessed 20 October 2012).
24. Abraham NS, Byrne CJ, Young JM, Solomon MJ,. Meta-analysis of well-designed nonrandomized comparative studies of surgical procedures is as good as randomized controlled trials. J Clin Epidemiol 2010; 63 (3): 238-245.
25. Higgins JPT, Green S,. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org (accessed 18 April 2012).
26. Wells GA, Shea B, O'Connell D, et al,. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp (accessed 18 April 2012).
27. Parmar MK, Torri V, Stewart L,. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17 (24): 2815-2834.
28. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR,. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16.
29. Riley RD, Higgins JP, Deeks JJ,. Interpretation of random effects meta-analyses. BMJ 2011; 342: d549.
30. Higgins JPT, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557-560.
31. Ioannidis JPA, Patsopoulos NA, Evangelou E,. Uncertainty in heterogeneity estimates in meta-analyses. BMJ 2007; 335 (7626): 914-916.
32. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H,. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002; 89 (4): 418-422.
33. Miyaguchi S, Watanabe T, Takahashi H, Nakamura M, Saito H, Ishii H,. Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. Hepatogastroenterology 2002; 49 (45): 724-729.
34. Shiratori Y, Shiina S, Teratani T, et al,. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138 (4): 299-306.
35. Nishiguchi S, Tamori A, Kubo S,. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005; 48 (1): 71-75.
36. Sun HC, Tang ZY, Wang L, et al,. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006; 132 (7): 458-465.
37. Lo CM, Liu CL, Chan SC, et al,. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245 (6): 831-842.
38. Ishikawa T, Higuchi K, Kubota T, et al,. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival. Hepatogastroenterology 2012; 59 (114): 529-532.
39. Suou T, Mitsuda A, Koda M, et al,. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res 2001; 20 (3): 301-311.
40. Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, Lu SN,. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol 2005; 20 (10): 1553-1559.
41. Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H, Kawasaki T,. Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005; 48 (1): 64-70.
42. Akamatsu M, Yoshida H, Shiina S, et al,. Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma. Liver Int 2006; 26 (5): 536-542.
43. Someya T, Ikeda K, Saitoh S, et al,. Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. J Gastroenterol 2006; 41 (12): 1206-1213.
44. Kudo M, Sakaguchi Y, Chung H, et al,. Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study. Oncology 2007; 72 (Suppl. 1): 132-138.
45. Jeong SC, Aikata H, Katamura Y, et al,. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 2007; 13 (40): 5343-5350.
46. Jeong S, Aikata H, Katamura Y, et al,. Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol 2007; 13 (39): 5188-5195.
47. Katagiri S, Tokushige K, Yamamoto M,. [Postoperative interferon therapy after resection of hepatitis C virus-related hepatocellular carcinoma]. Nihon Shokakibyo Gakkai Zasshi 2008; 105 (6): 795-801.
48. Ikeda K, Kobayashi M, Seko Y, et al,. Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: a retrospective study of hepatitis C virus-related liver cancer. Hepatol Res 2010; 40 (12): 1168-1175.
49. Qu LS, Jin F, Huang XW, Shen XZ,. Interferon-alpha therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma. J Surg Oncol 2010; 102 (7): 796-801.
50. Hagihara H, Nouso K, Kobayashi Y, et al,. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Clin Oncol 2011; 16 (3): 210-220.
51. Tanimoto Y, Tashiro H, Aikata H, et al,. Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection. Ann Surg Oncol 2012; 19 (2): 418-425.
52. European Association of the study of the liver. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int 2012; 32 (Suppl. 1): 2-8.
53. Ayoub WS, Keeffe EB,. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2011; 34 (10): 1145-1158.